# Mayne Pharma

The register now connects TWYNEO with the existing RHOFADE and EPSOLAY reviews. Their acne and rosacea records address different conditions and should be read with each product's own label and review date.

- **Canonical:** https://www.30plusskin.care/brands/mayne-pharma
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## The operation

- **Category:** PRESCRIPTION PHARMACEUTICALS · ACNE & ROSACEA
- **Model:** Named distributor in the current TWYNEO manufacturer label; medicine obtained through a prescription and pharmacy.
- **Products assessed:** 3
- **Mean score:** 74/100
- **Mean disclosure score:** 85/100
- **Pricing:** See each offer and billing period in the product records
- **Brand site:** https://www.twyneo.com/
- **REVIEW SCOPE:** 3 OFFERINGS · NOT A CATALOGUE AUDIT
- **RESEARCH CHECKED:** 13 SEPTEMBER 2026
- **METHOD:** PUBLIC-SOURCE DESK REVIEW
- **SCORE SCOPE:** SEE EACH REVIEW'S SCORED CRITERIA

## Verdict

The current manufacturer information identifies Mayne Pharma and a 30 g TWYNEO pump. Older Galderma documents remain discoverable, making the version of the source relevant to pack and handling information.

The reviewed TWYNEO label contains an unresolved inconsistency in one efficacy-table row. The product review records it rather than silently repairing a number or using it to claim superiority.

RHOFADE and EPSOLAY remain separate rosacea records in the register. Adding an acne product does not make their indications or study outcomes directly comparable. Read each assessment at its own review date.

## Patterns in the reviewed range

### 01 — Version the label, not just the brand name

Use the instructions supplied with the actual dispensed product. A historical approval document can establish an earlier record while giving a pack size or opening limit that differs from today's manufacturer information.

### 02 — Keep one product's scope visible

A disclosed formula and controlled trial do not provide an assessment of every medicine in a corporate catalogue. This profile connects the three reviewed records without treating them as a portfolio-wide audit.

## Credit where it is due

- Provides a full prescribing-information document.
- The label specifies formulation and handling details.

## Disclosure matrix

| Product | OFFICIAL SOURCE | PERSONAL OUTCOMES TESTED |
| --- | --- | --- |
| Mayne Pharma TWYNEO Cream | yes | no |
| Mayne Pharma Rhofade | yes | no |
| Mayne Pharma Epsolay | yes | no |

## Reviews

| No. | Product | Stance | Score | Price | Document |
| --- | --- | --- | --- | --- | --- |
| R-52 | Epsolay — Microencapsulated benzoyl peroxide cream 5% | RECOMMENDED | 81/100 | $563 | /reviews/epsolay-benzoyl-peroxide-review |
| R-75 | TWYNEO Cream | CONDITIONAL | 80/100 | Pharmacy quote | /reviews/twyneo-tretinoin-benzoyl-peroxide-review |
| R-41 | Rhofade — Oxymetazoline hydrochloride cream 1% | CAUTION | 62/100 | $150 | /reviews/rhofade-oxymetazoline-cream-review |

## Sources

- [TWYNEO — current manufacturer prescribing information](https://www.twyneo.com/pdf/20250617_tywneo_pi.pdf) — February 2025 label names Mayne Pharma and a 30 g pump. Trial 1 success and difference figures in Table 4 conflict; that row is not charted here. Storage limits are product-specific. Checked 13 September 2026.
- [FDA — original TWYNEO approval label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214902s000lbl.pdf) — Historical 2021 label used only to investigate the Trial 1 table discrepancy. Its older pack size and opening limit are not used for current purchasing advice. Checked 13 September 2026.

## Related records

- [R-41 Mayne Pharma Rhofade](/reviews/rhofade-oxymetazoline-cream-review)
- [R-52 Mayne Pharma Epsolay](/reviews/epsolay-benzoyl-peroxide-review)
- [R-75 Mayne Pharma TWYNEO Cream](/reviews/twyneo-tretinoin-benzoyl-peroxide-review)
- [R-74 Bausch Health CABTREO Gel](/reviews/cabtreo-acne-gel-review)
- [L-17 Adult acne prescription combinations: what the ingredients change](/ledger/adult-acne-prescription-combinations)
- [L-19 Prescription skincare expiry and storage: compare usable treatment time](/ledger/prescription-skincare-expiry-storage)

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._